Clinical Research Directory

Inclusion Criteria: * Luminal small bowel or colonic Crohn's disease in clinical remission * 16 years or older * MRE as part of routine care performed within three months prior, or one month after the decision to stop biologic therapy Anti-TNF (Adalimumab, infliximab, Certolizumab) IL-23 or IL-12 antagonists (Ustekinumab) Anti-integrin biologics (Natalizumab, Vedolizumab) * Biologic therapy stopped due to clinical remission only Definition of clinical remission: There is no agreed consensus on how clinical remission is defined and practice differs between hospitals and patients. To mirror current clinical practice, no strict definition of clinical remission will therefore be used. Detailed clinical parameters the time of stopping biologic agents will be collected. Exclusion Criteria: \<16 years of age Non-biological therapy, unless part of combination therapy with biologic agents Biological therapy stopped for other reasons e.g. loss of effect, side effects Resection of diseased segment(s) after MRE but before stopping biologic agent. No MRE with the time window defined by eligibility criteria